[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1323 Introduced in House (IH)]







106th CONGRESS
  1st Session
                                H. R. 1323

  To promote research to identify and evaluate the health effects of 
 silicone breast implants, and to ensure that women and their doctors 
           receive accurate information about such implants.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 25, 1999

Mr. Green of Texas (for himself, Mr. Sherman, Mr. Sanders, Mr. DeFazio, 
  Mr. Frost, Mr. LaFalce, Mr. Bentsen, Mr. Sandlin, Mr. Baldacci, Ms. 
Stabenow, Mr. Filner, Mr. Brown of Ohio, Mrs. Maloney of New York, Mr. 
   Underwood, Ms. Pelosi, Mr. Waxman, Mr. Shows, Mr. Jefferson, Mr. 
Lampson, Mr. McNulty, Ms. DeGette, Mr. Horn, Ms. Jackson-Lee of Texas, 
    Mrs. Thurman, Mr. Ford, Ms. Carson, Mr. Gilman, Mr. Maloney of 
   Connecticut, Mr. Rangel, Mr. Engel, Ms. Norton, Ms. Rivers, Mrs. 
 Emerson, Ms. Kaptur, Mr. Payne, Mr. Wynn, Mr. Pallone, Mr. Gonzalez, 
 Mrs. Wilson, Mr. Whitfield, Mr. Hulshof, and Mr. Kind) introduced the 
    following bill; which was referred to the Committee on Commerce

_______________________________________________________________________

                                 A BILL


 
  To promote research to identify and evaluate the health effects of 
 silicone breast implants, and to ensure that women and their doctors 
           receive accurate information about such implants.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Silicone Breast Implant Research and 
Information Act''.

SEC. 2. FINDINGS AND PURPOSE.

    (a) Findings.--Congress makes the following findings:
            (1) According to the Institute of Medicine, it is estimated 
        that 1,000,000 to 2,000,000 American women have received 
        silicone breast implants over the last 35 years.
            (2) Silicone breast implants have been used primarily for 
        breast augmentation, but also as an important part of 
        reconstruction surgery for breast cancer or other conditions.
            (3) Women with breast cancer or other medical conditions 
        seek access to the broadest possible treatment options, 
        including silicone breast implants.
            (4) Women need complete and accurate information about the 
        potential health risks and advantages of silicone breast 
        implants so that women can make informed decisions.
            (5) Although the rate of implant rupture and silicone 
        leakage has not been definitively established, estimates are as 
        high as 70 percent.
            (6) According to a 1997 Mayo Clinic study, 1 in 4 women 
        required additional surgery because of their implants within 5 
        years of receiving them.
            (7) In addition to potential systemic complications, local 
        changes in breast tissue such as hardening, contraction of scar 
        tissue surrounding implants, blood clots, severe pain, burning 
        rashes, serious inflammation, or other complications requiring 
        surgical intervention following implantation have been 
        reported.
            (8) According to the National Science Panel Report released 
        in December 1998, the current body of research on silicone 
        breast implants in immunology, rheumatology, toxicology, and 
        epidemiology is inadequate to conclusively determine the 
        effects of silicone. The National Science Panel pointed to many 
        limitations in research methodology and data analysis used in 
        past studies clearly demonstrating the need for future 
        independent clinical research.
            (9) According to the Institute of Medicine, concern remains 
        that exposure to silicone or other components in silicone 
        breast implants may result in currently undefined connective 
        tissue or autoimmune diseases.
            (10) A group of independent scientists and clinicians 
        convened by the National Institute of Arthritis and 
        Musculoskeletal and Skin Diseases in April of 1997 addressed 
        concerns that an association may exist between atypical 
        connective tissue disease and silicone breast implants, and 
        called for additional basic research on the components of 
        silicone as well as biological responses to silicone.
            (11) According to many reports, including a study published 
        in the Journal of the National Cancer Institute, the presence 
        of silicone breast implants may create difficulties in 
        obtaining complete mammograms.
            (12) According to a 1998 Food and Drug Administration 
        publication, although silicone breast implants usually do not 
        interfere with a woman's ability to nurse, if the implants 
        leak, there is some concern that the silicone may harm the 
        baby. Some studies suggest a link between breast feeding with 
        implants and problems with the child's esophagus.
    (b) Purpose.--It is the purpose of this Act to promote research to 
identify and evaluate the health effects of silicone breast implants, 
and to ensure that women and their doctors receive accurate information 
about such implants.
    (c) Rule of Construction.--Nothing in this Act shall be construed 
to affect any rule or regulation promulgated under the authority of the 
Federal Food, Drug and Cosmetic Act that is in effect on the date of 
enactment of this Act relating to the availability of silicone breast 
implants for reconstruction after mastectomy, correction of congenital 
deformities, or replacement for ruptured silicone implants for 
augmentation.

SEC. 3. EXPANSION AND INTENSIFICATION OF ACTIVITIES REGARDING SILICONE 
              BREAST IMPLANTS AT THE NATIONAL INSTITUTES OF HEALTH.

    Part H of title IV of the Public Health Service Act (42 U.S.C. 289 
et seq.) is amended by adding at the end the following:

``SEC. 498C. SILICONE BREAST IMPLANT RESEARCH.

    ``(a) Institute-Wide Coordinator.--The Director of NIH shall 
appoint an appropriate official of the Department of Health and Human 
Services to serve as the National Institutes of Health coordinator 
regarding silicone breast implant research. Such coordinator shall 
encourage and coordinate the participation of all appropriate 
Institutes in research on silicone breast implants, including--
            ``(1) the National Institute of Allergy and Infectious 
        Diseases;
            ``(2) the National Institute of Arthritis and 
        Musculoskeletal and Skin Diseases;
            ``(3) the National Institute of Child Health and Human 
        Development;
            ``(4) the National Institute of Environmental Health 
        Sciences;
            ``(5) the National Institute of Neurological Disorders and 
        Stroke; and
            ``(6) the National Cancer Institute.
    ``(b) Study Sections.--The Director of NIH shall establish a study 
section or special emphasis panel if determined to be appropriate, for 
the National Institutes of Health to review extramural research grant 
applications regarding silicone breast implants to ensure the 
appropriate design and high quality of such research and shall take 
appropriate action to ensure the quality of intramural research 
activities.
    ``(c) Clinical Study.--
            ``(1) In general.--The Director of NIH shall conduct or 
        support research to expand the understanding of the health 
        implications of silicone breast implants. Such research should, 
        if determined to be scientifically appropriate, include a 
        multidisciplinary, clinical, case-controlled study of women 
        with silicone breast implants. Such a study should involve 
        women who have had such implants in place for at least 8 years, 
        focus on atypical disease presentation, neurological 
        dysfunction, and immune system irregularities, and evaluate to 
        what extent if any, their health differs from that of suitable 
        controls, including women with saline implants as a subset.
            ``(2) Annual report.--The Director of NIH shall annually 
        prepare and submit to the appropriate Committees of Congress a 
        report concerning the results of the study conducted under 
        paragraph (1).''.

SEC. 4. EXPANSION AND INTENSIFICATION OF ACTIVITIES REGARDING SILICONE 
              BREAST IMPLANTS AT THE FOOD AND DRUG ADMINISTRATION.

    To assist women and doctors in receiving accurate and complete 
information about the risks of silicone breast implants, the 
Commissioner on Food and Drugs shall--
            (1) ensure that the toll-free Consumer Information Line and 
        materials concerning breast implants provided by the Food and 
        Drug Administration are available, up to date, and responsive 
        to reports of problems with silicone breast implants, and that 
        timely aggregate data concerning such reports shall be made 
        available to the public upon request and consistent with 
        existing confidentiality standards;
            (2) revise the Administration's breast implant information 
        update to clarify the procedure for reporting problems with 
        silicone implants or with the conduct of adjunct studies, and 
        specifically regarding the use of the Medwatch reporting 
        program;
            (3) require that manufacturers of silicone breast implants 
        update implant package inserts and informed consent documents 
        regularly to reflect accurate information about such implants, 
        particularly the rupture rate of such implants; and
            (4) require that any manufacturer of such implants that is 
        conducting an adjunct study on silicone breast implants--
                    (A) amend such study protocol and informed consent 
                document to reflect that patients must be provided with 
                a copy of informed consent documents at the initial, or 
                earliest possible, consultation regarding breast 
                prosthesis;
                    (B) amend the informed consent to inform women 
                about how to obtain a Medwatch form and encourage any 
                woman who withdraws from the study, or who would like 
                to report a problem, to submit a Medwatch form to 
                report such problem or concerns with the study and 
                reasons for withdrawing; and
                    (C) amend the informed consent document to provide 
                potential participants with the inclusion criteria for 
                the clinical trial and the toll-free Consumer 
                Information number.

SEC. 5. PRESIDENT'S INTERAGENCY COMMITTEE ON SILICONE BREAST IMPLANTS.

    (a) Establishment.--There is established an interagency committee, 
to be known as the President's Interagency Committee on Silicone Breast 
Implants (referred to in this Act as the ``Committee''), to ensure the 
strategic management, communication, and oversight of the policy 
formation, research, and activities of the Federal Government regarding 
silicone breast implants.
    (b) Composition.--The Committee shall be composed of--
            (1) an individual to be appointed by the President who 
        represents the White House domestic policy staff;
            (2) a representative, to be appointed by the Secretary of 
        Health and Human Services, from--
                    (A) the Office of Women's Health at the Department 
                of Health and Human Services;
                    (B) the National Institutes of Health;
                    (C) the Food and Drug Administration; and
                    (D) the Centers for Disease Control and Prevention;
            (3) a representative of the Department of Defense with 
        experience in the Department's breast cancer research program;
            (4) representatives of any other agencies deemed necessary 
        to accomplish the mission of the Committee, including the 
Social Security Administration if appropriate;
            (5) up to 4 individuals to be appointed by the President 
        from scientists with established credentials and publications 
        in the area of silicone breast implants; and
            (6) 2 women who have or have had silicone breast implants 
        to be appointed by the President.
    (c) Chairperson.--
            (1) In general.--The individual appointed under subsection 
        (b)(2)(A), or other official if the President determines that 
        such other official is more appropriate, shall service as the 
        chairperson of the Committee.
            (2) Duties.--The chairperson of the Committee shall--
                    (A) not less than twice each year, convene meetings 
                of the Committee; and
                    (B) compile information for the consideration of 
                the full Committee at such meetings.
    (d) Meetings.--The meetings of the Committee shall be open to the 
public and public witnesses shall be given the opportunity to speak and 
make presentations at such meetings. Each member of the Committee shall 
make a presentation to the full Committee at each such meeting 
concerning the activities conducted by such member or by the entity 
that such member is representing related to silicone breast implants.
    (e) Administrative Provisions.--
            (1) Terms and vacancies.--A member of the Committee shall 
        serve for a term of 2 or 4 years (rotating terms). A member may 
        be reappointed 2 times, but shall not exceed 8 years of 
        service. Any vacancy in the membership of the Committee shall 
        be filled in the manner in which the original appointment was 
        made and shall not affect the power of the remaining members to 
        carry out the duties of the Committee.
            (2) Compensation; reimbursement of expenses.--Members of 
        the Committee may not receive compensation for service on the 
        Committee. Such members may, in accordance with chapter 57 of 
        title 5, United States Code, be reimbursed for travel, 
        subsistence, and other necessary expenses incurred in carrying 
        out the duties of the Committee.
            (3) Staff; administrative support.--The Secretary of Health 
        and Human Services shall, on a reimbursable basis, provide to 
        the Committee such staff, administrative support, and other 
        assistance as may be necessary for the Committee to effectively 
        carry out the duties under this section.
            (4) Conflict of interest.--The members of the Committee 
        shall not be in violation of any Federal conflict of interest 
        laws.
    (f) Authorization of Appropriations.--There are authorized to be 
appropriated such sums as may be necessary to carry out this section.
                                 <all>